Stock CAH CARDINAL HEALTH, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Cardinal Health, Inc.

Equities

CAH

US14149Y1082

Pharmaceuticals

Market Closed - Nyse
Other stock markets
 04:00:02 2024-06-05 pm EDT 		5-day change 1st Jan Change
97.96 USD -0.37% Intraday chart for Cardinal Health, Inc. +1.89% -2.82%
May. 29 Transcript : Cardinal Health, Inc. Presents at 2024 Leerink Partners Healthcare Crossroads Conference, May-29-2024 08:00 AM
May. 29 Baird Adjusts Price Target on Cardinal Health to $129 From $128 MT

Valuation

Fiscal Period: June 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 14,039 15,239 16,565 14,240 24,078 23,860 - -
Enterprise Value (EV) 1 19,539 19,243 19,394 14,838 24,736 24,592 24,728 24,238
P/E ratio 10.4 x -4.14 x 27.4 x -15.6 x 94.6 x 24.9 x 15.8 x 13.8 x
Yield 4.06% 3.7% 3.41% 3.75% 2.1% 2.06% 2.08% 2.13%
Capitalization / Revenue 0.1 x 0.1 x 0.1 x 0.08 x 0.12 x 0.11 x 0.11 x 0.11 x
EV / Revenue 0.13 x 0.13 x 0.12 x 0.08 x 0.12 x 0.11 x 0.12 x 0.11 x
EV / EBITDA 7.15 x 6.94 x 7.5 x 6.29 x 10 x 8.67 x 8.31 x 7.48 x
EV / FCF 8.16 x 12.1 x 9.56 x 5.43 x 10.5 x 12.2 x 18.6 x 11.6 x
FCF Yield 12.3% 8.24% 10.5% 18.4% 9.53% 8.22% 5.36% 8.58%
Price to Book 1.63 x 8.55 x 9.29 x -20.6 x -8.32 x -8.44 x -11.8 x -14.6 x
Nbr of stocks (in thousands) 298,060 291,986 290,148 272,427 254,600 243,567 - -
Reference price 2 47.10 52.19 57.09 52.27 94.57 97.96 97.96 97.96
Announcement Date 8/8/19 8/6/20 8/5/21 8/11/22 8/15/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: June 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 145,534 152,922 162,467 181,364 205,012 225,702 209,984 226,837
EBITDA 1 2,732 2,773 2,587 2,358 2,464 2,835 2,976 3,238
EBIT 1 2,353 2,384 2,255 1,990 2,057 2,414 2,553 2,795
Operating Margin 1.62% 1.56% 1.39% 1.1% 1% 1.07% 1.22% 1.23%
Earnings before Tax (EBT) 1 1,751 -3,772 323 -769 638 1,131 1,442 1,751
Net income 1 1,363 -3,696 611 -933 261 949 1,402 1,588
Net margin 0.94% -2.42% 0.38% -0.51% 0.13% 0.42% 0.67% 0.7%
EPS 2 4.530 -12.61 2.080 -3.350 1.000 3.940 6.218 7.085
Free Cash Flow 1 2,394 1,585 2,029 2,735 2,358 2,021 1,326 2,081
FCF margin 1.64% 1.04% 1.25% 1.51% 1.15% 0.9% 0.63% 0.92%
FCF Conversion (EBITDA) 87.63% 57.16% 78.43% 115.99% 95.7% 71.28% 44.56% 64.25%
FCF Conversion (Net income) 175.64% - 332.08% - 903.45% 212.92% 94.56% 131.02%
Dividend per Share 2 1.910 1.929 1.948 1.960 1.988 2.021 2.041 2.091
Announcement Date 8/8/19 8/6/20 8/5/21 8/11/22 8/15/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: June 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2 2025 Q3 2025 Q4
Net sales 1 45,457 44,836 47,103 49,603 51,469 50,487 53,453 54,763 57,445 54,911 58,503 51,798 53,753 51,538 55,163
EBITDA 1 552 647 542 523 566 707 667 679 674 763 707.6 677.9 695.1 821.8 771.8
EBIT 1 467 545 450 423 467 606 560 571 562 666 610.6 595.5 609.5 711 658.1
Operating Margin 1.03% 1.22% 0.96% 0.85% 0.91% 1.2% 1.05% 1.04% 0.98% 1.21% 1.04% 1.15% 1.13% 1.38% 1.19%
Earnings before Tax (EBT) 1 -973 -137 -28 110 -137 544 121 -26 490 341 326 49.78 455.4 436.9 409.8
Net income 1 49 -1,391 138 110 -130 345 -64 5 353 258 328.5 374 389 467 410
Net margin 0.11% -3.1% 0.29% 0.22% -0.25% 0.68% -0.12% 0.01% 0.61% 0.47% 0.56% 0.72% 0.72% 0.91% 0.74%
EPS 2 0.1700 -5.050 0.5000 0.4000 -0.5000 1.340 -0.2500 0.0200 1.430 1.050 1.527 1.507 1.587 1.880 1.720
Dividend per Share 2 0.4908 0.4908 0.4908 0.4957 0.4957 0.4957 0.5006 0.5006 0.5006 0.5006 0.4991 0.5103 0.5116 0.5121 0.5214
Announcement Date 2/3/22 5/5/22 8/11/22 11/4/22 2/2/23 5/4/23 8/15/23 11/3/23 2/1/24 5/2/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: June 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 5,500 4,004 2,829 598 658 732 868 378
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 2.013 x 1.444 x 1.094 x 0.2536 x 0.267 x 0.2582 x 0.2916 x 0.1169 x
Free Cash Flow 1 2,394 1,585 2,029 2,735 2,358 2,021 1,326 2,081
ROE (net income / shareholders' equity) 25.7% 39.5% 91.3% 261% - - - -
ROA (Net income/ Total Assets) 3.93% 3.93% 3.84% 3.21% 3.48% 3.34% 3.44% 3.83%
Assets 1 34,703 -94,103 15,904 -29,039 7,500 28,436 40,818 41,443
Book Value Per Share 2 28.90 6.110 6.140 -2.540 -11.40 -11.60 -8.280 -6.730
Cash Flow per Share 2 9.040 6.690 8.260 11.20 10.80 12.20 10.70 11.40
Capex 1 328 375 400 387 481 502 496 515
Capex / Sales 0.23% 0.25% 0.25% 0.21% 0.23% 0.22% 0.24% 0.23%
Announcement Date 8/8/19 8/6/20 8/5/21 8/11/22 8/15/23 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Cardinal Health, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
97.96 USD
Average target price
111.9 USD
Spread / Average Target
+14.19%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Pharmaceuticals Wholesale

1st Jan change Capi.
CARDINAL HEALTH, INC. Stock Cardinal Health, Inc.
-2.82% 23.86B
MCKESSON CORPORATION Stock McKesson Corporation
+25.19% 75.34B
SINOPHARM GROUP CO. LTD. Stock Sinopharm Group Co. Ltd.
+8.07% 8.61B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD Stock Shanghai Pharmaceuticals Holding Co., Ltd
+10.64% 8.52B
HUADONG MEDICINE CO., LTD Stock Huadong Medicine Co., Ltd
-22.31% 7.78B
H. LUNDBECK A/S Stock H. Lundbeck A/S
+12.82% 5.18B
GALENICA AG Stock Galenica AG
+2.61% 4.13B
EBOS GROUP LIMITED Stock EBOS Group Limited
-5.04% 4.03B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD Stock Jointown Pharmaceutical Group Co., Ltd
+3.71% 3.82B
CHINA NATIONAL MEDICINES CORPORATION LTD. Stock China National Medicines Corporation Ltd.
+21.59% 3.62B
Pharmaceuticals Wholesale
  1. Stock Market
  2. Equities
  3. CAH Stock
  4. Financials Cardinal Health, Inc.